Loading
Led OVHIPEC-1, the trial that showed heated intraperitoneal chemotherapy at surgery extends survival in ovarian cancer.
Willemien van Driel was principal investigator of OVHIPEC-1, the Dutch randomised trial showing that adding hyperthermic intraperitoneal cisplatin to interval cytoreductive surgery improves recurrence-free and overall survival in stage III ovarian cancer, the first level-one evidence for HIPEC in the disease. She leads OVHIPEC-2 in the primary surgery setting.
| Title | Journal | Year |
|---|---|---|
| Hyperthermic intraperitoneal chemotherapy in ovarian cancer (OVHIPEC-1) | NEJM | 2018 |
| Overall survival after hyperthermic intraperitoneal chemotherapy for ovarian cancer: 10-year follow-up of OVHIPEC-1 | Lancet Oncology | 2023 |
Shares OVHIPEC-1, HIPEC / PIPAC (intraperitoneal chemotherapy), Ovarian cancer.
Shares Ovarian cancer and the tags ovarian, surgery.
Shares Ovarian cancer and the tags ovarian, surgery.
Shares HIPEC / PIPAC (intraperitoneal chemotherapy), Ovarian cancer.
Shares HIPEC / PIPAC (intraperitoneal chemotherapy), Ovarian cancer.
Shares Ovarian cancer and the tag ovarian.
Shares Ovarian cancer and the tag surgery.
Shares Ovarian cancer and the tag ovarian.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/